Home / Treatments / Tesamorelin / Providers
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Disclosure: we may earn a commission if you use certain links on this page. Compensation does not change our published methodology, scoring, or editorial conclusions.
Written by Kim Callender, NP, FNP-BC·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Prices verified July 12, 2026·Methodology v1.0

Tesamorelin telehealth providers: how to evaluate them

Direct answer

Tesamorelin is a GHRH analogue and — importantly — one of the few peptides in this category that is <b>genuinely FDA-approved</b>, though for a narrow indication: the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is marketed as Egrifta. Everything else it is sold for is off-label.

How to evaluate a Tesamorelin provider

We do not publish a ranked list of Tesamorelin providers, for a specific reason: we have not captured and dated their pricing or verified their pharmacy relationships. Publishing a ranking we cannot substantiate would be worth less than nothing.

What we can give you is the evaluation framework we apply to the providers we have verified — the 18 GLP-1 telehealth companies in our pricing database.

What separates a legitimate provider from a storefront
SignalWhat good looks likeWhat should worry you
Prescribing clinicianNamed, licensed, verifiable NPIUnnamed 'medical team'
Medical evaluationReal review; some patients are declinedA form that approves everyone
PharmacyNamed facility, licence verifiable in a state board database'Our network of licensed pharmacies'
FormulationSalt form and concentration disclosedWill not tell you
Regulatory languageStates plainly that compounded is not FDA-approved'FDA-approved pharmacy' — a meaningless phrase
Evidence claimsDistinguishes mechanism from demonstrated outcomeCites mouse studies as if they were human results
PricingTotal cost stated up front, cancellation terms publishedHeadline rate that turns out to be a first month

How to verify any of this yourself

You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.

  1. Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
  2. Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
  3. Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
  4. Ask what the highest dose costs. By email or chat, so you have it in writing.
  5. Ask about early cancellation before you commit to a plan longer than a month.
  6. Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.

If a provider will not answer questions 4 or 5 in writing, that is itself information.

Frequently asked questions

What does Tesamorelin cost through telehealth?

We have not verified a price and will not publish one we cannot substantiate. This page gives you the method to evaluate any quote you are given.

Is Tesamorelin FDA-approved?

Tesamorelin (Egrifta) is FDA-approved, for one specific indication: excess visceral abdominal fat in HIV-infected patients with lipodystrophy. This is the strongest regulatory position of any peptide on this site, and it deserves to be stated clearly.

It also deserv

Does Tesamorelin work?

The approval rests on real randomised trial data showing a meaningful reduction in visceral adipose tissue in the HIV-lipodystrophy population, with associated improvements in triglycerides. That evidence is good.

It is also specific. There is no comparable trial evide

Sources

  1. U.S. Food and Drug Administration — approved labels and compounding guidance for this molecule.
  2. PubMed / NIH — indexed human clinical literature.
  3. ClinicalTrials.gov — registered trials, where they exist.
  4. Our source hierarchy and pricing-verification methodology.

Spotted an error? Submit a correction.